Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
Authors
Keywords
-
Journal
Molecular Cancer
Volume 19, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-01-31
DOI
10.1186/s12943-020-1144-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The first-week proliferative response of peripheral blood PD-1+CD8+ T cells predicts the response to anti-PD-1 therapy in solid tumors
- (2019) Kyung Hwan Kim et al. CLINICAL CANCER RESEARCH
- Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
- (2019) Xianjie Jiang et al. Molecular Cancer
- Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy
- (2019) Aurelie Hanoteau et al. Journal for ImmunoTherapy of Cancer
- Indoleamine 2,3-dioxygenase 1 and Programmed Cell Death-ligand 1 Co-expression Predicts Poor Pathologic Response and Recurrence in Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy
- (2019) Sha Zhou et al. Cancers
- Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine release
- (2019) Shu Lian et al. EBioMedicine
- Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy
- (2019) Karin M. Knudson et al. Journal for ImmunoTherapy of Cancer
- HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1
- (2019) Chu-Yu Jing et al. Journal for ImmunoTherapy of Cancer
- CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function
- (2019) Deepak Mittal et al. Cancer Immunology Research
- Co-inhibitory T cell receptor KLRG1: human cancer expression and efficacy of neutralization in murine cancer models
- (2019) Steven A. Greenberg et al. Oncotarget
- The Aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy
- (2019) Gui-Zhen Wang et al. Nature Communications
- Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer
- (2019) Jun Zhao et al. Nature Communications
- Anti-PD1 up-regulates PD-L1 expression and inhibits T-cell lymphoma progression: possible involvement of an IFN-γ-associated JAK-STAT pathway
- (2019) Weili Xue et al. OncoTargets and Therapy
- TGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies
- (2019) María E. Rodríguez-Ruiz et al. MOLECULAR CANCER THERAPEUTICS
- Natural killer group 2D receptor and its ligands in cancer immune escape
- (2019) Shixin Duan et al. Molecular Cancer
- Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade
- (2019) Chien-Chun Steven Pai et al. IMMUNITY
- FDA Approval Summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors
- (2019) Leigh Marcus et al. CLINICAL CANCER RESEARCH
- Effects and mechanisms of innate immune molecules on inhibiting nasopharyngeal carcinoma
- (2019) Fang Xiong et al. CHINESE MEDICAL JOURNAL
- Lycopene improves the efficiency of anti-PD-1 therapy via activating IFN signaling of lung cancer cells
- (2019) Xiufeng Jiang et al. Cancer Cell International
- Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets
- (2019) Luca Cassetta et al. CANCER CELL
- TSC22D2 identified as a candidate susceptibility gene of multi-cancer pedigree using genome-wide linkage analysis and whole exome sequencing
- (2019) Lan Xiao et al. CARCINOGENESIS
- Adaptive plasticity of IL-10+ and IL-35+ Treg cells cooperatively promotes tumor T cell exhaustion
- (2019) Deepali V. Sawant et al. NATURE IMMUNOLOGY
- Genetic diversity of tumors with mismatch repair deficiency influences anti–PD-1 immunotherapy response
- (2019) Rajarsi Mandal et al. SCIENCE
- Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer
- (2019) Jessica Konen et al. Cancers
- Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy
- (2019) Heng-Huan Lee et al. CANCER CELL
- Long non-coding RNA PVT1 interacts with MYC and its downstream molecules to synergistically promote tumorigenesis
- (2019) Ke Jin et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- PVT1 Promotes Cancer Progression via MicroRNAs
- (2019) Wenxi Wang et al. Frontiers in Oncology
- Neoantigen vaccine: an emerging tumor immunotherapy
- (2019) Miao Peng et al. Molecular Cancer
- Durable Response After Combination Of Concurrent Chemoradiotherapy And Anti-PD-1 Therapy In HER2-Negative Advanced Gastric Adenocarcinoma: A Case Report
- (2019) Shanshan Yu et al. OncoTargets and Therapy
- Tumor mutational burden analysis of 2,000 Japanese cancer genomes using whole exome and targeted gene panel sequencing
- (2018) Keiichi HATAKEYAMA et al. BIOMEDICAL RESEARCH-TOKYO
- Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy
- (2018) T. Finazzi et al. BMC CANCER
- Extratumoral PD-1 blockade does not perpetuate obesity-associated inflammation in esophageal adenocarcinoma
- (2018) Karen C. Galvin et al. CANCER LETTERS
- Interleukin-35 Suppresses the Antitumor Activity of T Cells in Patients with Non-Small Cell Lung Cancer
- (2018) Hong-Min Wang et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma
- (2018) Erik Ladomersky et al. CLINICAL CANCER RESEARCH
- Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non–Small-Cell Lung Cancer
- (2018) Alona Zer et al. Clinical Lung Cancer
- Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors
- (2018) Jooeun Bae et al. LEUKEMIA
- TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
- (2018) Daniele V. F. Tauriello et al. NATURE
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
- (2018) Dai Fukumura et al. Nature Reviews Clinical Oncology
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- (2018) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells
- (2018) Qi Lai et al. ONCOGENE
- Programmed death ligand 1 promotes lymph node metastasis and glucose metabolism in cervical cancer by activating integrin β4/SNAI1/SIRT3 signaling pathway
- (2018) Shaojia Wang et al. ONCOGENE
- The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
- (2018) Vyara Matson et al. SCIENCE
- CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade
- (2018) Limo Chen et al. Cancer Discovery
- Indoleamine 2,3-Dioxygenase Expression Pattern in the Tumor Microenvironment Predicts Clinical Outcome in Early Stage Cervical Cancer
- (2018) A. Marijne Heeren et al. Frontiers in Immunology
- RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer
- (2018) Elizabeth Ahern et al. OncoImmunology
- Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2
- (2018) Na Luo et al. OncoImmunology
- Intratumoral injection of activated B lymphoblast in combination with PD-1 blockade induces systemic antitumor immunity with reduction of local and distal tumors
- (2018) Mario M Soldevilla et al. OncoImmunology
- Combination with SGT-53 overcomes tumor resistance to a checkpoint inhibitor
- (2018) Sang-Soo Kim et al. OncoImmunology
- Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas
- (2018) Maud Toulmonde et al. JAMA Oncology
- Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
- (2018) Mariaelena Capone et al. Journal for ImmunoTherapy of Cancer
- Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma
- (2018) Ritu Shrestha et al. Frontiers in Oncology
- Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors
- (2018) Shan Xie et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Identification of genomic alterations in nasopharyngeal carcinoma and nasopharyngeal carcinoma-derived Epstein–Barr virus by whole-genome sequencing
- (2018) Chaofeng Tu et al. CARCINOGENESIS
- Notch signaling pathway suppresses CD8+ T cells activity in patients with lung adenocarcinoma
- (2018) Shuo Li et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
- (2018) Gang Chen et al. NATURE
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- Prognostic factors of daily blood examination for advanced melanoma patients treated with nivolumab
- (2018) Hisako Okuhira et al. BioScience Trends
- A positive correlation between the EZH2 and PD-L1 expression in resected lung adenocarcinomas
- (2018) Gouji Toyokawa et al. ANNALS OF THORACIC SURGERY
- Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report
- (2018) Haibo Mou et al. BMC CANCER
- A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
- (2018) Miguel F. Sanmamed et al. CELL
- Targeting PIM Kinase with PD1 inhibition Improves Immunotherapeutic Antitumor T-cell Response
- (2018) Shilpak Chatterjee et al. CLINICAL CANCER RESEARCH
- Radiotherapy with the anti-programmed cell death ligand-1 immune checkpoint blocker avelumab: acute toxicities in triple-negative breast cancer
- (2018) Eliana La Rocca et al. MEDICAL ONCOLOGY
- Effects of tumor metabolic microenvironment on regulatory T cells
- (2018) Yi-an Wang et al. Molecular Cancer
- Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)
- (2018) Marcin Kowanetz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- (2018) Razvan Cristescu et al. SCIENCE
- Lin−CCR2+ hematopoietic stem and progenitor cells overcome resistance to PD-1 blockade
- (2018) Catherine T. Flores et al. Nature Communications
- Application of atomic force microscopy in cancer research
- (2018) Xiangying Deng et al. JOURNAL OF NANOBIOTECHNOLOGY
- Somatic Mutations and Immune Alternation in Rectal Cancer Following Neoadjuvant Chemoradiotherapy
- (2018) Dengbo Ji et al. Cancer Immunology Research
- Acquired resistance to immunotherapy in MMR-D pancreatic cancer
- (2018) Zishuo Ian Hu et al. Journal for ImmunoTherapy of Cancer
- A nomogram-based immunoprofile predicts overall survival for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy
- (2018) Jingjing Duan et al. Journal for ImmunoTherapy of Cancer
- Analysis of non-small cell lung cancer microenvironment indicates preponderance of T cell exhaustion marker expression
- (2017) Hui Zhou et al. EXPERIMENTAL CELL RESEARCH
- Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma
- (2017) Suzanne George et al. IMMUNITY
- Tumor CDKN2A-Associated JAK2 Loss and Susceptibility to Immunotherapy Resistance
- (2017) Susanne Horn et al. JNCI-Journal of the National Cancer Institute
- Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade
- (2017) Esra A. Akbay et al. Journal of Thoracic Oncology
- Genome-Wide Analysis of 18 Epstein-Barr Viruses Isolated from Primary Nasopharyngeal Carcinoma Biopsy Specimens
- (2017) Chaofeng Tu et al. JOURNAL OF VIROLOGY
- Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
- (2017) Jacob Schachter et al. LANCET
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
- (2017) Michael J Overman et al. LANCET ONCOLOGY
- Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer
- (2017) Gustavo Schvartsman et al. LUNG CANCER
- Pneumonitis in cancer patients receiving anti-PD-1 and radiotherapies
- (2017) Chieh-Sheng Lu et al. MEDICINE
- Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression,N-glycosylation and Expression Stoichiometry with PD-1 and PD-L2 in Human Melanoma
- (2017) Carlos A. Morales-Betanzos et al. MOLECULAR & CELLULAR PROTEOMICS
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
- (2017) Aaron M. Goodman et al. MOLECULAR CANCER THERAPEUTICS
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
- (2017) V. Gopalakrishnan et al. SCIENCE
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
- (2017) Florie Bertrand et al. Nature Communications
- Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions
- (2017) Antje Sucker et al. Nature Communications
- Resistance to checkpoint blockade therapy through inactivation of antigen presentation
- (2017) Moshe Sade-Feldman et al. Nature Communications
- Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
- (2017) Scott Gettinger et al. Cancer Discovery
- The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy
- (2017) Daniel Zingg et al. Cell Reports
- Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
- (2017) Angel Garcia-Diaz et al. Cell Reports
- Tumor CDKN2A-Associated JAK2 Loss and Susceptibility to Immunotherapy Resistance
- (2017) Susanne Horn et al. JNCI-Journal of the National Cancer Institute
- Increasing Tumor-Infiltrating T Cells through Inhibition of CXCL12 with NOX-A12 Synergizes with PD-1 Blockade
- (2017) Dirk Zboralski et al. Cancer Immunology Research
- PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
- (2017) Hashem O. Alsaab et al. Frontiers in Pharmacology
- High numbers of PDCD1 (PD-1)-positive T cells and B2M mutations in microsatellite-unstable colorectal cancer
- (2017) Jonas Janikovits et al. OncoImmunology
- Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition
- (2017) Florine A. Eggink et al. OncoImmunology
- A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer
- (2017) David L. Rimm et al. JAMA Oncology
- Deubiquitination and Stabilization of PD-L1 by CSN5
- (2016) Seung-Oe Lim et al. CANCER CELL
- Checkpoint Antibodies but not T Cell-Recruiting Diabodies Effectively Synergize with TIL-Inducing -Irradiation
- (2016) M. Hettich et al. CANCER RESEARCH
- Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
- (2016) Jianjun Gao et al. CELL
- Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
- (2016) Joseph L. Benci et al. CELL
- Reversing T-cell Dysfunction and Exhaustion in Cancer
- (2016) H. M. Zarour CLINICAL CANCER RESEARCH
- Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition
- (2016) Jiangtao Ren et al. CLINICAL CANCER RESEARCH
- Microsatellite Instability as a Biomarker for PD-1 Blockade
- (2016) J. C. Dudley et al. CLINICAL CANCER RESEARCH
- Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N
- (2016) Jacquelyn Smith et al. Diagnostic Pathology
- Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
- (2016) Lars Hofmann et al. EUROPEAN JOURNAL OF CANCER
- PD-1 inhibitor gastroenterocolitis: case series and appraisal of ‘immunomodulatory gastroenterocolitis’
- (2016) Raul S Gonzalez et al. HISTOPATHOLOGY
- Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer
- (2016) Janice M. Mehnert et al. JOURNAL OF CLINICAL INVESTIGATION
- PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non–Small Cell Lung Cancer
- (2016) Seiichi Ikeda et al. Journal of Thoracic Oncology
- Role of adenosine A2b receptor overexpression in tumor progression
- (2016) Cesar Sepúlveda et al. LIFE SCIENCES
- Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer
- (2016) Jamaal A Rehman et al. MODERN PATHOLOGY
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- The oncolytic peptide LTX-315 triggers immunogenic cell death
- (2016) H Zhou et al. Cell Death & Disease
- Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
- (2016) P.-L. Chen et al. Cancer Discovery
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
- (2016) Daniel Sanghoon Shin et al. Cancer Discovery
- Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer
- (2016) Gulidanna Shayan et al. OncoImmunology
- Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
- (2016) Joseph McLaughlin et al. JAMA Oncology
- IDO1 is an Integral Mediator of Inflammatory Neovascularization
- (2016) Arpita Mondal et al. EBioMedicine
- IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer
- (2015) K Abiko et al. BRITISH JOURNAL OF CANCER
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges
- (2015) Feifei Teng et al. CANCER LETTERS
- Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer
- (2015) Kristin J. Lastwika et al. CANCER RESEARCH
- PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors
- (2015) Kevin C. Soares et al. JOURNAL OF IMMUNOTHERAPY
- Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
- (2015) Nan Chen et al. Journal of Thoracic Oncology
- Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma
- (2015) Jianwei Zhang et al. MEDICAL ONCOLOGY
- A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme
- (2015) Sang-Soo Kim et al. Nanomedicine-Nanotechnology Biology and Medicine
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
- (2015) Jan A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
- (2015) M. Vetizou et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
- (2015) W. Peng et al. Cancer Discovery
- Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses
- (2015) Paul A. Beavis et al. Cancer Immunology Research
- Association of Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1
- (2015) Brooke E. Howitt et al. JAMA Oncology
- Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
- (2015) Luisa Carbognin et al. PLoS One
- A Nanoparticle Carrying the p53 Gene Targets Tumors Including Cancer Stem Cells, Sensitizes Glioblastoma to Chemotherapy and Improves Survival
- (2014) Sang-Soo Kim et al. ACS Nano
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
- (2014) R. Salgado et al. ANNALS OF ONCOLOGY
- Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
- (2014) Rakesh K. Jain CANCER CELL
- Prognostic B-cell Signatures Using mRNA-Seq in Patients with Subtype-Specific Breast and Ovarian Cancer
- (2014) M. D. Iglesia et al. CLINICAL CANCER RESEARCH
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Interferon Receptor Signaling in Malignancy: A Network of Cellular Pathways Defining Biological Outcomes
- (2014) E. N. Fish et al. MOLECULAR CANCER RESEARCH
- Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy
- (2014) S. L. Highfill et al. Science Translational Medicine
- Emerging patterns of somatic mutations in cancer
- (2013) Ian R. Watson et al. NATURE REVIEWS GENETICS
- PTEN functions as a melanoma tumor suppressor by promoting host immune response
- (2013) Y Dong et al. ONCOGENE
- Immunogenic Cell Death in Cancer Therapy
- (2012) Guido Kroemer et al. Annual Review of Immunology
- Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
- (2012) D. S. Chen et al. CLINICAL CANCER RESEARCH
- Modulation of Inflammatory Immune Reactions by Low-Dose Ionizing Radiation: Molecular Mechanisms and Clinical Application
- (2012) F. Rodel et al. CURRENT MEDICINAL CHEMISTRY
- Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis
- (2012) L. C. W. Vredeveld et al. GENES & DEVELOPMENT
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Inhibitory Receptor PD-1 Regulates IgA Selection and Bacterial Composition in the Gut
- (2012) S. Kawamoto et al. SCIENCE
- BrafV600E cooperates with Pten loss to induce metastatic melanoma
- (2009) David Dankort et al. NATURE GENETICS
- Immunogenic death of colon cancer cells treated with oxaliplatin
- (2009) A Tesniere et al. ONCOGENE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started